Renal cell carcinoma accounts for approximately 90% of kidney cancers, and current treatments fail to prevent metastasis in up to 40% of patients. Potentially effective is immunotherapy based on CAR T cells that recognize CD70, which is little expressed in normal tissues but is expressed in more than 80% of renal cell carcinomas. However, such CAR T immunotherapy has so far not shown overwhelming success against renal cell carcinoma, and the therapeutic cells must be derived for each patient individually.
Perseus Proteomics Inc. and Ube Corp. have disclosed antibody-drug conjugates (ADCs) comprising antibodies T004b-PGAP-1 targeting human P-cadherin (CDH3) targeting covalently linked to cytotoxic drug through a linker reported to be useful for the treatment of cancer.
The oncofetal antigen 5T4 is a cell surface glycoprotein overexpressed in many solid tumors, while its expression in normal tissues is limited, making it an attractive target for cancer therapies. Its association with tumor progression and poor prognosis further supports its therapeutic potential.
Clarivate plc has unveiled the 2025 Citation Laureates. Widely considered a predictor of the Nobel Prizes, this recognition has highlighted the discovery of biomolecular condensates in chemistry and the innate immunity signaling pathway in physiology or medicine, as well as the identification of leukemia stem cells and ghrelin, the so-called hunger hormone.
The U.S. FDA approved Merck & Co. Inc.’s Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) injection on Sept. 19, making it the first and only subcutaneously (SC)-administered immune checkpoint inhibitor that can be administered in about a minute.
Glioblastoma, the most aggressive and lethal form of brain cancer in adults, has long evaded effective treatment due to its resistance to standard therapies, including surgical resection, radiation, chemotherapy and targeted agents.
A recently published study in the Journal for Immunotherapy of Cancer presents a novel bispecific antibody-cytokine fusion protein that effectively enhances antitumor immunity.
The U.S. FDA approved Merck & Co. Inc.’s Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) injection on Sept. 19, making it the first and only subcutaneously (SC)-administered immune checkpoint inhibitor that can be administered in about a minute.
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has divulged antibody-drug conjugates (ADCs) comprising antibodies targeting human mucin-17 (MUC17) covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
Osteosarcoma, the most common bone cancer in children and young adults, has poor outcomes after relapse with only ~18% 5-year survival, underscoring the urgent need for new therapies. Researchers from New York Medical College and colleagues have now demonstrated a new strategy to improve the efficacy of natural killer (NK) cell-based immunotherapy for osteosarcoma.
RSS
